Search - tctmd.com

Displaying 1 - 20 of 331

Sort: Relevancy | Date

News Conference News TCT 2016

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

Michael O'Riordan

November 08, 2016

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Industry News TCT 2016

Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

November 02, 2016

Presentation TCT 2016

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Fernando Alfonso

November 02, 2016

News Conference News TCT 2016

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

Michael O'Riordan

November 02, 2016

Presentation TCT 2016

TRANSFORM-OCT: A Prospective, Randomized Trial Using OCT Imaging to Evaluate Strut Coverage at Three Months and Neoatherosclerosis at Eighteen Months in Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Giulio Guagliumi

November 02, 2016

Presentation TCT 2016

Choose a Drug-Eluting Stent: Heres Why

Presenter: George D. Dangas, Fabio Felice Tarantino, Carlo Cernetti

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: PLATINUM DIVERSITY

Presenter: Philip M. Urban, Stephen G. Worthley, Bonnie H. Weiner

November 01, 2016

Presentation TCT 2016

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Stephen G. Ellis

November 01, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Presenter: Philip M. Urban, Stephen G. Worthley, Robert-Jan van Geuns

November 01, 2016

Presentation TCT 2016

Bare Metal and 1st Generation Drug-Eluting Stents: Devices, Indications, and Outcomes

Presenter: Dmitriy N. Feldman, Emmanouil S. Brilakis

November 01, 2016

Presentation TCT 2016

Highlights (And my Interpretations) From: Polymer-free DES - LEADERS-free 2-year and RevElution

Presenter: Philip M. Urban, Stephen G. Worthley, Christian M. Spaulding

November 01, 2016

Presentation TCT 2016

Highlights (And my Interpretations) From: DES Comparisons BIO-RESORT (TWENTE III) and BIONICS

Presenter: Philip M. Urban, Stephen G. Worthley, Sigmund Silber

November 01, 2016

Presentation TCT 2016

TCT 313: Incidence and Predictors of Very Late Major Adverse Cardiac Events After Metallic Stents: A Patient-Level Pooled Analysis from Seventeen Randomized Trials

Presenter: Serban Puricel, Clemens von Birgelen

November 01, 2016

Presentation TCT 2016

TCT 312: Increased Cardiac Death and Stent Thrombosis in Chronic Obstructive Pulmonary Disease Patients Undergoing Percutaneous Coronary Intervention. An Analysis of the BASKET-PROVE I and II trials.

Presenter: Serban Puricel, Clemens von Birgelen

November 01, 2016

Presentation TCT 2016

TCT 401: Bioresorbable Scaffolds And Thrombosis: Insights From The GHOST-EU (Gauging coronary Healing with Bioresorbable Scaffolding Platforms in Europe) Registry

Presenter: Serban Puricel, Clemens von Birgelen

November 01, 2016

Presentation TCT 2016

TCT 402: Relationship Between Bioresorbable Scaffold Sizing and Scaffold Thrombosis: A Pooled Analysis of ABSORB Trials

Presenter: Serban Puricel, Clemens von Birgelen

November 01, 2016

Presentation TCT 2016

Percutaneous Coronary Intervention with the ANgiolite Drug-Eluting Stent: an Optical CoHerence TOmogRaphy Study. The ANCHOR Study

Presenter: Fernando Alfonso, Ran Kornowski, Josep Rodés-Cabau

November 01, 2016

Presentation TCT 2016

TCT 276: Prevalence and 5-Year Outcomes of Full Metal Jacket Drug-Eluting Stenting for Coronary Chronic Total Occlusion

Presenter: Mauro Carlino, Alfredo R. Galassi

October 31, 2016

Presentation TCT 2016

TCT 263: Impact of Diabetes on Clinical Outcomes in Patients Undergoing Unprotected Left Main Percutaneous Coronary Intervention with Drug-Eluting Stents

Presenter: Kevin J. Beatt, Frederick Feit

October 31, 2016

Advertisement

RIBS VI: Absorb BVS Safe in In-Stent Restenosis but Fails to Best Xience Metallic Stent

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

RIBS VI: A Prospective, Multicenter Registry of Bioresorbable Vascular Scaffolds in Patients With Coronary Artery Bare Metal or Drug-Eluting In-Stent Restenosis Six Month-Nine Month Clinical and Angiographic Follow-up Results

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

TRANSFORM-OCT: A Prospective, Randomized Trial Using OCT Imaging to Evaluate Strut Coverage at Three Months and Neoatherosclerosis at Eighteen Months in Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

Choose a Drug-Eluting Stent: Heres Why

Highlights (and my Interpretations) From: PLATINUM DIVERSITY

Highlights (and My Interpretations) From: Absorb BVS - ABSORB II and ABSORB China (2-3 Year Results)

Highlights (and my Interpretations) From: New BRS - FANTOM II, MeRes-1, FORTITUDE and FUTURE-I (6-9 Month Results)

Bare Metal and 1st Generation Drug-Eluting Stents: Devices, Indications, and Outcomes

Highlights (And my Interpretations) From: Polymer-free DES - LEADERS-free 2-year and RevElution

Highlights (And my Interpretations) From: DES Comparisons BIO-RESORT (TWENTE III) and BIONICS

TCT 313: Incidence and Predictors of Very Late Major Adverse Cardiac Events After Metallic Stents: A Patient-Level Pooled Analysis from Seventeen Randomized Trials

TCT 312: Increased Cardiac Death and Stent Thrombosis in Chronic Obstructive Pulmonary Disease Patients Undergoing Percutaneous Coronary Intervention. An Analysis of the BASKET-PROVE I and II trials.

TCT 401: Bioresorbable Scaffolds And Thrombosis: Insights From The GHOST-EU (Gauging coronary Healing with Bioresorbable Scaffolding Platforms in Europe) Registry

TCT 402: Relationship Between Bioresorbable Scaffold Sizing and Scaffold Thrombosis: A Pooled Analysis of ABSORB Trials

Percutaneous Coronary Intervention with the ANgiolite Drug-Eluting Stent: an Optical CoHerence TOmogRaphy Study. The ANCHOR Study

TCT 276: Prevalence and 5-Year Outcomes of Full Metal Jacket Drug-Eluting Stenting for Coronary Chronic Total Occlusion

TCT 263: Impact of Diabetes on Clinical Outcomes in Patients Undergoing Unprotected Left Main Percutaneous Coronary Intervention with Drug-Eluting Stents

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content